Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $45.00 target price on the stock.

Several other analysts have also weighed in on ORKA. Stifel Nicolaus began coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Wedbush reissued an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. TD Cowen started coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Finally, Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Trading Down 2.2 %

Oruka Therapeutics stock opened at $20.31 on Friday. The company’s fifty day simple moving average is $24.55. The stock has a market capitalization of $710.83 million, a P/E ratio of -3.24 and a beta of 0.78. Oruka Therapeutics has a 52-week low of $18.20 and a 52-week high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics during the 3rd quarter worth about $1,037,000. FMR LLC purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $114,763,000. Great Point Partners LLC bought a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $12,614,000. Braidwell LP bought a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $12,640,000. Finally, Janus Henderson Group PLC bought a new position in Oruka Therapeutics in the third quarter worth approximately $5,840,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.